Comparing Surgery and Infliximab for Crohn's Disease
Author Information
Author(s): Eshuis Emma J, Bemelman Willem A, van Bodegraven Ad A, Sprangers Mirjam AG, Bossuyt Patrick MM, de Wit AW Marc van Milligen, Crolla Rogier MPH, Cahen Djuna L, Oostenbrug Liekele E, Sosef Meindert N, Voorburg Annet MCJ, Davids Paul HP, van der Woude C Janneke, Lange Johan, Mallant Rosalie C, Boom Maarten J, Lieverse Rob J, van der Zaag Edwin S, Houben Martin HMG, Vecht Juda, Pierik Robert EGJM, van Ditzhuijsen Theo JM, Prins Hubert A, Marsman Willem A, Stockmann Henricus B, Brink Menno A, Consten Esther CJ, van der Werf Sjoerd DJ, Marinelli Andreas WKS, Jansen Jeroen M, Gerhards Michael F, Bolwerk Clemens JM, Stassen Laurents PS, Spanier BW Marcel, Bilgen Ernst Jan Spillenaar, van Berkel Anne-Marie, Cense Huib A, van Heukelem Henk A, van de Laar Arnold, Slot Warner Bruins, Eijsbouts Quirijn A, van Ooteghem Nancy AM, van Wagensveld Bart, van den Brande Jan MH, van Geloven Anna AW, Bruin Karien F, Maring John K, Oldenburg Bas, van Hillegersberg Richard, de Jong Dirk J, Bleichrodt Robert, van der Peet Donald L, Dekkers Pascal EP, Goei T Hauwy, Stokkers Pieter CF
Primary Institution: Academic Medical Center, Amsterdam, The Netherlands
Hypothesis
Is laparoscopic ileocolic resection more effective than infliximab treatment for recurrent Crohn's disease of the distal ileum?
Conclusion
The study aims to determine whether infliximab treatment or surgery is the better option for patients with recurrent distal ileitis in Crohn's disease.
Supporting Evidence
- Infliximab is effective but expensive for treating Crohn's disease.
- Surgery can provide quick relief of symptoms.
- Quality of life is a primary outcome measure in the study.
- Patients will be followed for 12 months to assess outcomes.
- Randomization will help ensure unbiased treatment assignment.
- Infliximab treatment may lead to long-term dependency on medication.
- Surgical resection may reduce the need for ongoing medical treatment.
- Both treatment strategies will be compared for cost-effectiveness.
Takeaway
This study is trying to find out if surgery or medicine is better for people with a certain type of stomach problem called Crohn's disease.
Methodology
A multicenter randomized clinical trial comparing infliximab treatment and laparoscopic ileocolic resection in patients with recurrent Crohn's disease.
Potential Biases
Potential bias in patient selection and randomization process.
Limitations
The study may not account for long-term outcomes beyond one year.
Participant Demographics
Patients aged 18 to 80 with recurrent Crohn's disease of the distal ileum.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website